Q2 2025 Earnings Forecast for Hologic, Inc. Issued By Zacks Research (NASDAQ:HOLX)

Hologic, Inc. (NASDAQ:HOLX) – Stock analysts at Zacks Research upped their Q2 2025 earnings per share estimates for shares of Hologic in a note issued to investors on Wednesday, April 10th. Zacks Research analyst R. Anand now expects that the medical equipment provider will post earnings per share of $1.11 for the quarter, up from their prior estimate of $1.10. The consensus estimate for Hologic’s current full-year earnings is $4.02 per share. Zacks Research also issued estimates for Hologic’s FY2025 earnings at $4.28 EPS.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping the consensus estimate of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $989.32 million. During the same period last year, the firm posted $1.07 earnings per share. The business’s revenue was down 5.7% compared to the same quarter last year.

Several other equities research analysts have also recently weighed in on the company. UBS Group raised their price target on Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Wednesday, April 10th. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and upped their price target for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. Raymond James raised their price target on shares of Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. Finally, Evercore ISI upped their price objective on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $87.00.

Hologic Stock Performance

NASDAQ HOLX opened at $77.54 on Monday. The firm has a market cap of $18.20 billion, a price-to-earnings ratio of 36.75, a PEG ratio of 2.62 and a beta of 1.00. The company has a 50-day simple moving average of $75.64 and a two-hundred day simple moving average of $72.42. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55. Hologic has a 12-month low of $64.02 and a 12-month high of $87.88.

Insiders Place Their Bets

In related news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now directly owns 1,572 shares in the company, valued at $119,802.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the sale, the director now directly owns 48,611 shares in the company, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,846 shares of company stock worth $2,473,443. Company insiders own 1.75% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Washington Capital Management Inc. bought a new stake in Hologic in the first quarter worth $618,000. Ballentine Partners LLC grew its position in Hologic by 7.4% during the 1st quarter. Ballentine Partners LLC now owns 3,941 shares of the medical equipment provider’s stock valued at $307,000 after purchasing an additional 273 shares during the last quarter. Congress Asset Management Co. MA increased its stake in Hologic by 7.5% during the 1st quarter. Congress Asset Management Co. MA now owns 1,247,946 shares of the medical equipment provider’s stock valued at $97,290,000 after purchasing an additional 86,935 shares in the last quarter. Tealwood Asset Management Inc. raised its holdings in Hologic by 2.1% in the first quarter. Tealwood Asset Management Inc. now owns 15,882 shares of the medical equipment provider’s stock worth $1,238,000 after buying an additional 328 shares during the last quarter. Finally, Marcum Wealth LLC purchased a new position in Hologic in the first quarter worth about $201,000. Institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.